- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07752732
Non-Interventional Study on the Prevalence of Cardiac Amyloidosis in Patients With Higher-Grade Aortic Valve Stenosis - Evaluation Using Echocardiography, Computed Tomography, Tc99-SPECT/CT and Cardiac Magnetic Resonance Imaging (CMR) (NIS-TAVI-AMY)
Degenerative aortic stenosis (AS) is frequently accompanied by left ventricular hypertrophy and diastolic dysfunction, features that overlap with transthyretin (ATTR) cardiac amyloidosis. Because concomitant cardiac amyloidosis may adversely affect outcomes after transcatheter aortic valve implantation (TAVI), its early detection is clinically important.
This prospective observational study aims to evaluate multimodal imaging biomarkers for the detection and characterization of cardiac amyloidosis in patients with severe AS undergoing TAVI evaluation. Clinically indicated technetium-99m phosphonate SPECT/CT and CT will be used to assess the presence and extent of cardiac amyloidosis, including quantitative measures of myocardial tracer uptake and extracellular volume. In patients with abnormal findings, cardiac magnetic resonance imaging (CMR) will be performed as an additional non-invasive imaging modality according to institutional clinical practice.
The study will determine the prevalence of cardiac amyloidosis in this population and investigate the diagnostic and prognostic value of imaging-derived quantitative parameters. Standardized clinical follow-up at 6, 12, and 24 months will assess associations between imaging biomarkers and clinical outcomes. The study is observational and does not alter routine clinical management or diagnostic pathways.
Studieoversikt
Status
Detaljert beskrivelse
Degenerative aortic valve stenosis (AS) is currently the most common heart valve disease in western countries. It is defined as aortic valve opening area <1.0cm² and/or an average gradient of 40mmHg. Elderly patients with higher-grade AS are primarily treated interventionally by means of transcatheter aortic valve implantation (TAVI). The outcome here does not seem to be any worse compared to conventional/cardiac aortic valve replacement. A hallmark of higher grade AS is left ventricular hypertrophy. In addition, there is often a restrictive filling pattern, which can be demonstrated in echocardiography. These characteristics are also found in cardiac amyloidosis of the TTR type (transthyretin type). Amyloid was found in over 70% of surgically removed heart valves in patients who received an aortic valve replacement. The detection of amyloid is of clinical importance for the patient, since there are different therapeutic approaches depending on the respective amyloid form. Endomyocardial biopsy (EMB) is currently the gold standard for the detection of cardiac amyloidosis in many places. However, it is an invasive procedure with associated risks and limitations (e.g. sampling error). Cardiac amyloidosis can be recognized non-invasively by the calcium-associated storage of technetium 99m (Tc99m)-labelled phosphonates, as is traditionally used in skeletal scintigraphy. According to the previous data, Tc99m phosphonate scintigraphy using SPECT/CT has a high specificity for the detection of TTR amyloidosis. If a SPECT/CT is available, this non-invasive diagnostic procedure is preferred to EMB.
The previous data indicate a correlation between the prognosis and the phosphonate storage in the myocardium. Using the Perugini score, the tracer uptake is only classified as a discrete size in a rough grid. A quantification of myocardial radiopharmaceutical intake could provide quantitative parameters that not only better reflect the severity of cardiac amyloidosis, but could also serve as a prognostic parameter. Such a quantification could take place through hybrid imaging using SPECT/CT, in which the anatomical information from computer tomography (CT) is combined with the functional information from single photon emission tomography (SPECT). This quantification takes place in a post-processing of the acquired data sets.
In addition to Tc99-SPECT/CT, cardiac MRI (CMR) with its excellent tissue characterization can also display inflammatory and fibrotic changes in the heart muscle, as can occur in amyloidosis as part of protein deposition. In addition to the established late gadolinium enhancement (LGE) technique, which can primarily map focal fibrotic processes with high accuracy, current CMR techniques for tissue characterization (T1/T2 mapping) can also be used to quantify diffuse myocardial changes, and distinguish fibrotic from inflammatory changes of the heart muscle by T1 or T2 weighting. If the Tc99-SPECT/CT findings are noticeable, a subsequent CMR is carried out for verification at the UKT as standard. This is the case in approximately 10% of patients.
If early detection of cardiac amyloidosis is assured, the clinical course of the patient could possibly be positively influenced by timely adequate therapy.
The aim of this study is to first determine the prevalence of cardiac amyloidosis using SPECT/CT and, if available, to quantify it. In patients with conspicuous SPECT/CT, the multimodal CMR is then (still) more likely to make possible cardiac amyloidosis as a second non-invasive method. The standardized follow-up after 6 or 12/24 months is planned to check the parameters determined by imaging technology (Tc99-SPECT/CT (or CMR)) for their prognostic relevance.
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Patrick Krumm, Prof. Dr. med.
- Telefonnummer: +49 7071 29 68119
- E-post: patrick.krumm@med.uni-tuebingen.de
Studer Kontakt Backup
- Navn: Studienzentrum Bildgebung Radiology
- Telefonnummer: +49 7071 29 85251
- E-post: studienzentrum-radiologie@med.uni-tuebingen.de
Studiesteder
-
-
-
Tübingen, Tyskland, 72076
- Rekruttering
- University Hospital of Tuebingen
-
Ta kontakt med:
- Jan M. Brendel, PD Dr. med.
- Telefonnummer: +49 7071 29 68528
- E-post: jan.brendel@med.uni-tuebingen.de
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Patients with severe aortic valve stenosis (valve opening area <1 cm², pmean >40 mmHg, Vmax >4 m/sec)
- Suspected cardiac amyloidosis
- Performance of one or more of the following imaging examinations due to (justifiable) clinical indication: echocardiography, photon-counting computed tomography (CT), Tc99-SPECT/CT, cardiac MRI
- Age ≥18 years
- Written consent of the patient for prospective data collection regarding Tc99-SPECT/CT, CT, and, if applicable, CMR and follow-up
Exclusion Criteria:
• patients unable to give consent
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Patients with higher grade aortic stenosis
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of Participants Diagnosed with Cardiac Amyloidosis
Tidsramme: At baseline
|
Presence of cardiac amyloidosis as determined by the study imaging protocol and diagnostic criteria.
The prevalence will be reported as the proportion of participants diagnosed with cardiac amyloidosis among patients with severe aortic valve stenosis.
|
At baseline
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants Experiencing Adverse Cardiac Events
Tidsramme: Up to 2 years after enrollment
|
Occurrence of major adverse cardiovascular events during follow-up.
The prognostic value of the imaging examinations will be assessed.
|
Up to 2 years after enrollment
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Patrick Krumm, Prof. Dr. med., University Hospital of Tuebingen
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Aortaklaffsykdom
- Sykdommer i nervesystemet
- Vaskulære sykdommer
- Kardiovaskulære sykdommer
- Patologiske tilstander, anatomiske
- Hjertesykdommer
- Nevromuskulære sykdommer
- Metabolisme, medfødte feil
- Genetiske sykdommer, medfødte
- Metabolske sykdommer
- Sykdommer i det perifere nervesystemet
- Nevrodegenerative sykdommer
- Hjerteklaffsykdommer
- Ventrikulær utstrømningsobstruksjon
- Heredodegenerative lidelser, nervesystemet
- Proteostase mangler
- Koronar sykdom
- Myokardiskemi
- Amyloide nevropatier
- Amyloidose, familiær
- Medfødte, arvelige og neonatale sykdommer og abnormiteter
- Patologiske tilstander, tegn og symptomer
- Ernæringsmessige og metabolske sykdommer
- Aortaklaffstenose
- Innsnevring, patologisk
- Koronar stenose
- Amyloidose
- Amyloide neuropatier, familiær
Andre studie-ID-numre
- 766/2019BO2
- DRKS00020481 (Annen identifikator: DRKS, German Clinical Trials Register)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .